Combined lanreotide autogel and temozolomide in progressive neuroendocrine tumours: An interim safety analysis of the SONNET study

The requested reference [dad7e44da6af212dea959801e6b64b5cc6980c2f] no longer exists in our database. It has been replaced by the current reference: [4262e9377fe36e531703a7bc975649e1c1359b9b]

Authors
Category Primary study
ConferenceOncology Research and Treatment
Year 2017
This article has no abstract
Epistemonikos ID: 7c1c455268995d9159e7a9c94a6a3a868dbc054e
First added on: Apr 29, 2026